Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 4:26 pm Sale | 2026-03-31 | 13G | EYEPOINT INC EYPT | Paradigm BioCapital Advisors LP | 3,142,437 3.800% | -1,049,824 (-25.04%) | Filing History |
| 2026-05-15 4:25 pm Sale | 2026-03-31 | 13G | UROGEN PHARMA LTD URGN | Paradigm BioCapital Advisors LP | 1,703,949 3.500% | -2,512,135 (-59.58%) | Filing History |
| 2026-05-15 4:25 pm Purchase | 2026-03-31 | 13G | LEXEO THERAPEUTICS INC LXEO | Paradigm BioCapital Advisors LP | 6,184,134 8.300% | 1,420,936 (+29.83%) | Filing History |
| 2026-05-15 4:25 pm Sale | 2026-03-31 | 13G | ERASCA INC ERAS | Paradigm BioCapital Advisors LP | 10,392,702 3.300% | -4,766,393 (-31.44%) | Filing History |
| 2026-05-11 4:02 pm Purchase | 2026-05-04 | 13G | ASSEMBLY BIOSCIENCES INC N ASMB | Paradigm BioCapital Advisors LP | 865,251 5.400% | 865,251 (New Position) | Filing History |
| 2026-04-24 8:12 pm Purchase | 2026-04-17 | 13G | ACHIEVE LIFE SCIENCES INC ACHV | Paradigm BioCapital Advisors LP | 9,903,712 9.200% | 9,903,712 (New Position) | Filing History |
| 2026-04-01 4:00 pm Purchase | 2026-03-25 | 13G | MAZE THERAPEUTICS INC MAZE | Paradigm BioCapital Advisors LP | 3,051,087 6.100% | 3,051,087 (New Position) | Filing History |
| 2026-02-24 4:00 pm Purchase | 2026-02-17 | 13G | EYEPOINT INC EYPT | Paradigm BioCapital Advisors LP | 4,192,261 5.100% | 4,192,261 (New Position) | Filing History |
| 2026-02-17 4:03 pm Sale | 2025-12-31 | 13G | MERUS N V COM MRUS | Paradigm BioCapital Advisors LP | 0 0.000% | -4,673,770 (Position Closed) | Filing History |
| 2026-02-17 4:03 pm Purchase | 2025-12-31 | 13G | ARCELLX INC ACLX | Paradigm BioCapital Advisors LP | 5,724,016 9.900% | 924,016 (+19.25%) | Filing History |
| 2026-02-17 4:02 pm Purchase | 2025-12-31 | 13G | EDGEWISE THERAPEUTICS INC EWTX | Paradigm BioCapital Advisors LP | 6,541,210 6.200% | 1,802,281 (+38.03%) | Filing History |
| 2026-02-17 4:02 pm Unchanged | 2025-12-31 | 13G | VOR BIOPHARMA INC VOR | Paradigm BioCapital Advisors LP | 1,750,000 4.500% | 0 (Unchanged) | Filing History |
| 2026-02-17 4:02 pm Purchase | 2025-12-31 | 13G | LEXEO THERAPEUTICS INC LXEO | Paradigm BioCapital Advisors LP | 4,763,198 6.500% | 1,091,199 (+29.72%) | Filing History |
| 2026-01-14 4:30 pm Purchase | 2026-01-07 | 13G | ERASCA INC ERAS | Paradigm BioCapital Advisors LP | 15,159,095 5.300% | 15,159,095 (New Position) | Filing History |
| 2025-11-20 4:30 pm Purchase | 2025-11-13 | 13G | LEXEO THERAPEUTICS INC LXEO | Paradigm BioCapital Advisors LP | 3,671,999 5.000% | 3,671,999 (New Position) | Filing History |
| 2025-11-18 4:30 pm Purchase | 2025-11-11 | 13G | VOR BIOPHARMA INC VOR | Paradigm BioCapital Advisors LP | 1,750,000 8.600% | 1,750,000 (New Position) | Filing History |
| 2025-11-14 4:34 pm Sale | 2025-09-30 | 13G | COGENT BIOSCIENCES INC COGT | Paradigm BioCapital Advisors LP | 3,156,398 2.300% | -7,196,051 (-69.51%) | Filing History |
| 2025-11-14 4:34 pm Sale | 2025-09-30 | 13G | AGIOS PHARMACEUTICALS INC AGIO | Paradigm BioCapital Advisors LP | 2,873,555 4.900% | -154,422 (-5.10%) | Filing History |
| 2025-11-14 4:34 pm Sale | 2025-09-30 | 13G | CIDARA THERAPEUTICS INC NE CDTX | Paradigm BioCapital Advisors LP | 961,164 3.300% | -167,449 (-14.84%) | Filing History |
| 2025-11-14 4:32 pm Sale | 2025-09-30 | 13G | LENZ THERAPEUTICS INC LENZ | Paradigm BioCapital Advisors LP | 1,073,461 3.800% | -346,371 (-24.40%) | Filing History |